MedPredict publishes report on RA treatment market

Arizona, USA-based market research organization MadPredict has published a report which examines the current state of the rheumatoid arthritis therapy market. The document contains expert opinion from physician experts in North America and Europe, in particular discussing the likely impact of the the interleukin-6 receptor antagonist Actemra (tocilizumab), currently being developed by Roche and Chugai, on the sector.

MedPredict president Jeffrey Berk commented that "this report sets the bar for next-generation biologicals and oral small molecules, and offers insight into a diverse group of clinical candidates based on potency, side effects, selective tissue compartmentalization and a host of other factors."